Online Public Access Catalogue (OPAC)
Library,Documentation and Information Science Division

“A research journal serves that narrow

borderland which separates the known from the unknown”

-P.C.Mahalanobis


Image from Google Jackets

Bayesian designs for phase I-II clinical trials / Ying Yuan, Hoang Q. Nguyen, and Peter F. Thall.

By: Contributor(s): Material type: TextTextSeries: Chapman & Hall/CRC biostatistics seriesPublication details: Boca Raton : CRC Press, ©2016.Description: xiv, 310 p. : illustrations ; 24 cmISBN:
  • 9781498709552
Subject(s): DDC classification:
  • 000SB:615.5 23 Y94
Contents:
1. Why conduct phase I-II trials? -- 2. The phase I-II paradigm -- 3. Establishing priors -- 4. Efficacy : toxicity trade-off-based designs -- 5. Designs with late-onset outcomes -- 6. Utility-based designs -- 7. Personalized dose finding -- 8. Combination trials -- 9. Optimizing molecularly targeted agents -- 10. Optimizing doses in two cycles -- 11. Optimizing dose and schedule -- 12. Dealing with dropouts -- 13. Optimizing intra-arterial tPA -- 14. Optimizing sedative dose in preterm infants.
Summary: This book describes how phase I–II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes. The first two chapters minimize the technical language to make them accessible to non-statisticians. These chapters discuss the severe drawbacks of the conventional paradigm used for early-phase clinical trials and explain the phase I–II paradigm for optimizing dose, or more general treatment regimes, based on both efficacy and toxicity. The remainder of the book covers a wide variety of clinical trial methodologies, including designs to optimize the dose pair of a two-drug combination, jointly optimize dose and schedule, identify optimal personalized doses, optimize novel molecularly targeted agents, and choose doses in two treatment cycles.
Tags from this library: No tags from this library for this title. Log in to add tags.

Includes bibliographical references and index.

1. Why conduct phase I-II trials? --
2. The phase I-II paradigm --
3. Establishing priors --
4. Efficacy : toxicity trade-off-based designs --
5. Designs with late-onset outcomes --
6. Utility-based designs --
7. Personalized dose finding --
8. Combination trials --
9. Optimizing molecularly targeted agents --
10. Optimizing doses in two cycles --
11. Optimizing dose and schedule --
12. Dealing with dropouts --
13. Optimizing intra-arterial tPA --
14. Optimizing sedative dose in preterm infants.

This book describes how phase I–II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.
The first two chapters minimize the technical language to make them accessible to non-statisticians. These chapters discuss the severe drawbacks of the conventional paradigm used for early-phase clinical trials and explain the phase I–II paradigm for optimizing dose, or more general treatment regimes, based on both efficacy and toxicity. The remainder of the book covers a wide variety of clinical trial methodologies, including designs to optimize the dose pair of a two-drug combination, jointly optimize dose and schedule, identify optimal personalized doses, optimize novel molecularly targeted agents, and choose doses in two treatment cycles.

There are no comments on this title.

to post a comment.
Library, Documentation and Information Science Division, Indian Statistical Institute, 203 B T Road, Kolkata 700108, INDIA
Phone no. 91-33-2575 2100, Fax no. 91-33-2578 1412, ksatpathy@isical.ac.in